Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Evolus, Inc. (NASDAQ:EOLS) has been given an average rating of “Moderate Buy” by the six research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $14.50.

EOLS has been the subject of several analyst reports. Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. BTIG Research reiterated a “buy” rating and set a $13.00 price target on shares of Evolus in a report on Wednesday, June 17th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC raised its holdings in Evolus by 1.6% in the 4th quarter. Nantahala Capital Management LLC now owns 5,820,649 shares of the company’s stock worth $38,707,000 after acquiring an additional 93,792 shares during the period. Caligan Partners LP boosted its holdings in Evolus by 23.8% during the third quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock valued at $25,413,000 after acquiring an additional 796,973 shares during the period. Vanguard Group Inc. boosted its holdings in Evolus by 3.3% during the third quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock valued at $21,054,000 after acquiring an additional 110,693 shares during the period. Braidwell LP acquired a new stake in shares of Evolus in the fourth quarter valued at about $20,650,000. Finally, Soleus Capital Management L.P. grew its position in shares of Evolus by 96.4% in the second quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock valued at $19,516,000 after purchasing an additional 1,039,842 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Evolus

Here are the key news stories impacting Evolus this week:

• Positive Sentiment: Strong quarterly growth and improved profitability: Second-quarter revenue rose 21.2% year over year to approximately $84.1 million, ahead of estimates. Gross profit reached $57.2 million, while the operating and net losses narrowed from the prior year. Evolus also delivered its third consecutive quarter of positive adjusted EBITDA. Evolus Reports Strong Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year outlook raised: Evolus issued 2026 revenue guidance of $330 million to $337 million, broadly ahead of the approximately $330.4 million analyst consensus, supporting the company’s growth narrative. Evolus Full-Year 2026 Outlook
• Positive Sentiment: Product momentum and market expansion: Management cited double-digit growth for Jeuveau and accelerating adoption of Evolysse. An expanded Symatese partnership will commercialize the Estyme hyaluronic-acid injectable portfolio in Canada, Australia and New Zealand, adding to Evolus’ international growth opportunities. Evolus Expands Strategic Partnership With Symatese
• Neutral Sentiment: Mixed institutional positioning: Recent filings showed 74 institutional investors adding shares and 76 reducing positions, indicating active but divided professional-investor sentiment.
• Negative Sentiment: Quarterly EPS missed expectations: Adjusted diluted EPS was a loss of $0.12, compared with the consensus loss estimate of $0.04. Operating cash flow was also negative at $3.6 million, and total liabilities increased to $278.9 million. Evolus Q2 2026 Earnings
• Negative Sentiment: Insider selling remains a risk signal: Company insiders reported sales but no purchases over the past six months, potentially tempering enthusiasm around the earnings-driven advance.

Evolus Price Performance

NASDAQ EOLS opened at $6.18 on Thursday. Evolus has a fifty-two week low of $3.86 and a fifty-two week high of $7.95. The stock’s 50-day moving average is $6.46 and its two-hundred day moving average is $5.51. The firm has a market cap of $407.01 million, a P/E ratio of -9.22 and a beta of 1.35.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $73.14 million during the quarter, compared to the consensus estimate of $72.52 million. During the same period in the previous year, the business posted ($0.30) EPS. On average, equities analysts expect that Evolus will post -0.38 EPS for the current year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.